HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Rectal Cancer. According to GlobalData, Phase I drugs for Rectal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HCW-9218 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HCW-9218 overview
HCW-9218 is under development for the treatment of metastatic pancreatic cancer, other solid tumors including rectal cancer, refractory breast cancer, ovarian cancer, colorectal cancer, prostate cancer, liver cancer, senile lentigo. It is administered through subcutaneous route. The drug candidate is a heterodimeric, bifunctional fusion protein complex TGF-beta combined with IL-15 and is developed based on TOBI (Tissue factor based fusion) platform which acts by targeting transforming growth factor beta (TGF-beta).
It was under development for melanoma, type 2 diabetes and idiopathic pulmonary fibrosis, non-alcoholic fatty liver disease (NAFLD), epithelial ovarian, fallopian or primary peritoneal cancer.
HCW Biologics overview
HCW Biologics is a developer of immunotherapy platforms to activate the immune system in order to disrupt the links between aging and disease. HCW Biologics is headquartered in Miramar, Florida, the US.
For a complete picture of HCW-9218’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
